New York, New York (PRWEB) May 04, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the legal rights of victims of defective medical devices, reports that the first bellwether trial in the C.R. Bard Inc. Pelvic Repair System Products Liability Litigation (MDL 2187) has been scheduled to start on February 5, 2013. Currently, 600 lawsuits naming Bard Avaulta transvaginal mesh products are pending in the litigation in the U.S. District Court for the Southern District of West Virginia. The date for the first Bard Avaulta transvaginal mesh trial was set by U.S. District Judge Joseph R. Goodwin in an Order dated May 1, 2012. [wvsd.uscourts.gov/mdl/2187/pdfs/PTO_35.pdf]
Judge Goodwin is overseeing three other transvaginal mesh device MDLs, including those manufactured by American Medical Systems, Inc. (MDL No. 2325), Boston Scientific Corp. (MDL No. 2326) and Ethicon, Inc., a unit of Johnson & Johnson (MDL No. 2327). All of the lawsuits pending in the litigations allege that the transvaginal mesh devices used in pelvic organ prolapse (POP) and stress urinary incontinence (SUI) repair surgeries caused women to suffer serious complications, including vaginal erosion, inflammation, infection, chronic pain and organ damage.
According to Parker Waichman LLP, bellwether trials are used when a large group of plaintiffs have filed suit based on the same theories or claims. Verdicts in these key trials will help gauge how juries might rule in similar transvaginal mesh lawsuits pending in the Bard Avaulta litigation.
In October 2008, the U.S. Food & Drug Administration (FDA) announced that it had begun a review of transvaginal mesh products, after receiving more than 1,000 reports of complications related to the use of the devices in the surgical repair of POP and SUI. In July 2011, the FDA announced that it had received an additional 1,503 reports of transvaginal mesh complications associated with POP repairs and an additional 1,371 reports associated with SUI repairs. The most common side effects reported to the FDA included erosion through the vaginal tissue, pain, infection, bleeding, pain during intercourse, organ perforation and urinary problems. The FDA also emphasized that POP transvaginal mesh complications are not rare, a change from the position it took in 2008. [fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm]
On September 8 and 9, 2011, the FDA’s Obstetrics and Gynecology Devices Advisory Panel met to discuss the safety of transvaginal mesh devices in POP repair. Though no formal vote was taken, the majority of outside medical experts on the panel backed the FDA’s proposal to reclassify transvaginal mesh devices as high risk. In January 2012, the FDA directed the makers of transvaginal mesh products, including C.R. Bard, to conduct post-market safety studies of their devices in order to enable the agency to better understand their safety and effectiveness profiles. [fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/default.htm]
Parker Waichman LLP continues to offer free lawsuit consultations to victims of transvaginal mesh injuries. If you or a loved one experienced complications following POP and SUI surgery with transvaginal mesh, please visit the firm’s transvaginal mesh injury page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding transvaginal mesh lawsuits and Parker Waichman LLP, please visit http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney